Welcome to Tehran Chemie Pharmaceuticals Website

Bioequivalence studies

Bioequivalence studies

TehranChemie is providing bioequivalence and pharma cokinetic studies through cooperation and partnerships.These studies are in compliance with current good clinical practice(cGCP),current good laboratory practice(cGLP),and other applicable guidelines and regulations.The full Bioequivalence study service covers:
 Wide selection of appropriate study designs
 The writing of study protocol
 Designing of case report forms (CRF)
 Management of Independent Ethics Committee reviews
 Selection and care for subjects
 Bioassay of drug/metabolite
 Pharmacokinetic and statistical data evaluation
 Reporting of study results and archiving of all trial-related data

Abnormal pancreatic beta cell function to release adequate insulin hormone, parallel to rising glycaemia is a key aspect in type 2 diabetes mellitus. This functional islet inadequacy progresses over time if not treated.
366 million adults with diabetes worldwide in 2011 were estimated to rise to 552 million in 2030, according to IDF. However, 93% rate increase in Africa and 85% in the Middle East and North Africa in 2014 increased the prevalence to already 425 million in 2017.
Future Forecast
The global Antidiabetic drug market is valued at 49.6$ billion in 2017 and will reach 96.7$ billion by the end of 2025, growing at a CAGR of 10% during 2018-2025.
Bringing More Satisfaction to patients
We are constantly looking for new approaches as effective medicines to treat diabetes mellitus.Available Tehran ChemieAntidiabetic medication brands are as the following:
  • Acarmax®
  • Glibotex®
  • Glizitex®
  • GlizitexER®
  • Metfortex®
  • Metfortex® ER
  • Hypotazone®
New generation
  • Januvex®
  • Jardipa®
Combination Therapies
  • Glycomin®
  • Janumix®
Cardiovascular diseases (CVDs) comprise disorders and conditions related to circulatory system which include heart and vascular system.Sedentary lifestyle, changing dietary habits and surge in associated risk factors are likely to increase the number of patients with cardiovascular diseases.
According to the Centers for Disease Control and Prevention (CDC) of the U.S., high blood pressure, high cholesterol, and smoking are key risk factors for heart disease. About half of the population of the U.S. (47%) has at least one of these three risk factors, affecting about 600,000 people each year. More than 85 million Americans are living with some form of cardiovascular disease or stroke, and by 2030, more than 40 percent of the US population is expected to have some form of CVD, a prevalence increase of 10 percent.
Future Forecast
The global cardiovascular drugs market was valued approximately US$ 80.0 Bnin 2016 and is anticipated to register CAGR of over 1.0% from 2017 to 2025 to reach value of approximately US$ 91.0 Bnby 2025. Drug classes used to treat cardiovascular indications such as hyperlipidemia, hypertension are likely to fuel expansion of the global cardiovascular drugs market from 2017 to 2025.
Bringing More Satisfaction to patients
We are constantly looking for new approaches as effective medicines to treat cardiovascular diseases. Available Tehran ChemieCardiovascular medication brands are as the following:
  • Spidacton®
  • Bisofar®
  • Angiovasc®
  • Enoxarin®
  • Xarivan®
Lipid-lowering agents
  • Atostrol®
  • Rosutex®
  • Sivastrol®
  • Lovastrol®
Combination therapies
  • Amlodipine5mg+Atorvastatin10mg
  • Amlodipine5mg+Atorvastatin20mg
Gastrointestinal diseases are those that affect any section of the gastrointestinal tract, from the esophagus to the rectum, andthe accessory digestive organs (liver, gall bladder and pancreas).
35-40% of world’s total population is suffering from acute or chronic GI complication.
Future Forecast
Due to nonpermanent cure for IBD and IBS syndromes, market growth of GI drugs is expected to grow at CAGR of 4.8% during forecasted period 2017-2023. It is estimated to reach till 59.3$ Billion by end of 2023.
Bringing More Satisfaction to patients
We are constantly looking for new approaches as effective medicines to treat GI disorders. Available Tehran Chemiegastrointestinal medication brands are as the following:
  • Devomit®
  • Demetic®
  • Demitron®
  • Apremitron®
  • EsoneX®
  • Pomizol®
  • Pentomid®
  • RabimizoL®
  • Hyotex®
  • Onanzim®
Treatment ofDiarrhea
  • Lomoxilate®


  • Writing patient leaflet for new products based on the scientific references
  • Preparing medical and scientific data in order to support the sales & marketing teams with up to date information
  • Preparing materials such as posters and patient information booklets
  • Answering patients and healthcare professionals’questions about company’sproducts and scientific subjects are answered by medical team members
  • Team work and collaborating with marketing departments
Wishlist 0
Open Wishlist Page Continue Shopping